Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from WVE

3 Pharma Stocks to Watch as Gene Therapy Gains Momentum

The pharma market shows promise as gene therapy gains momentum through rapid advancements that address complex diseases and improve treatment options. Given this favorable trend, it could be wise to watch strong pharma stocks such as Vertex Pharmaceuticals (VRTX), Wave Life Sciences (WVE), and Poseida Therapeutics (PSTX). Read more.

3 Pharma Stocks Outperforming the Competition

3 Pharma Stocks Outperforming the Competition

The growing demand for innovative drugs, the use of advanced technologies, and growing global healthcare needs boost the pharmaceutical industry’s long-term growth prospects. Therefore, fundamentally strong pharma stocks Viatris (VTRS), Wave Life Sciences (WVE), and MEI Pharma (MEIP) might be ideal additions to your portfolio. Read on.

4 Sky-Rocketing Pharma Stocks to Watch

4 Sky-Rocketing Pharma Stocks to Watch

The pharmaceutical industry is experiencing significant growth due to the rising demand for quality healthcare and high-quality drugs. This surge is further supported by the rapid growth in the global elderly population and the increase in chronic illnesses. Therefore, investors could consider adding pharma stocks Spero Therapeutics (SPRO), Wave Life…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

3 Smart Pharma Picks Serving Gains

With rising healthcare expenditure, growing need for precision medicine, innovations in biologics and gene editing, and rapid adoption of advanced technologies, the pharma industry is well-poised for significant growth and expansion. Thus, quality pharma stocks Wave Life (WVE), Teva Pharmaceuticals (TEVA), and Collegium (COLL) could be smart buys for substantial…

Bullish or Bearish: 3 Pharma Options

The pharmaceutical industry’s robust outlook is driven by high healthcare spending globally, consistent R&D efforts, and the rapid adoption of advanced digital technologies. So, let’s analyze if investors should adopt a bullish or bearish stance on pharma stocks such as Tilray Brands (TLRY), CytomX Therapeutics (CTMX), and Wave Life Sciences…

3 Solid Pharma Stocks for a Healthy Year-End Portfolio

The pharma industry is transforming due to the rapid adoption of AI and global healthcare spending, fostering innovation and patient care advancements. Therefore, fundamentally sound pharma stocks Eli Lilly (LLY), Wave Life Sciences (WVE) and Johnson & Johnson (JNJ) might be worth adding to boost your portfolio. Continue reading.

3 Pharma Stocks Navigating Future Investments - Buy Now

The pharmaceutical industry is evolving with changing consumer behavior, rapid adoption of digital solutions, and global expansion. Hence, fundamentally strong pharma stocks Zoetis (ZTS), Wave Life Sciences (WVE), and Johnson & Johnson (JNJ) might be solid investments now. Read more….

inkl

Read news from The Economist, FT, and more,
with one subscription

3 Pharma Stocks to Buy for a Smart Investment

3 Pharma Stocks to Buy for a Smart Investment

With the rise of chronic diseases and technological advancements, the pharma market looks poised for substantial expansion. So, fundamentally strong pharma stocks Kiniksa Pharmaceuticals (KNSA), Collegium Pharmaceutical (COLL), and Wave Life Sciences (WVE) might be solid buys. Keep reading.

3 Pharma Stocks to Buy in 2023 and Hold for Decades

3 Pharma Stocks to Buy in 2023 and Hold for Decades

The pharmaceutical industry is well-positioned for significant growth in the near future, given the growing demand for medicines and increasing R&D activities. Given the industry's inelastic demand, fundamentally strong pharma stocks AstraZeneca (AZN), Bristol-Myers Squibb (BMY), and GSK plc (GSK) might be solid long-term investments. Continue reading….

Ahead Of Upcoming Data On Three Programs, Analysts Remain On Sidelines For Wave Life Sciences

Ahead Of Upcoming Data On Three Programs, Analysts Remain On Sidelines For Wave Life Sciences

RBC Capital writes that Wave Life Sciences Ltd's (NASDAQ: WVE) Q1 earnings are largely incremental.

Recap: WAVE Life Sciences Q1 Earnings

Recap: WAVE Life Sciences Q1 Earnings

WAVE Life Sciences (NASDAQ:WVE) reported its Q1 earnings results on Thursday, May 12, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

WAVE Life Sciences Earnings Preview

WAVE Life Sciences Earnings Preview

WAVE Life Sciences (NASDAQ:WVE) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that WAVE Life Sciences will report an earnings per share (EPS) of $-0.55.

Wave Life Sciences Jump As Low Doses of WVE-004 Lowers Disease Biomarker In Neurological Indications

Wave Life Sciences Jump As Low Doses of WVE-004 Lowers Disease Biomarker In Neurological Indications

Wave Life Sciences Ltd's (NASDAQ: WVE)

WAVE Life Sciences's Return On Capital Employed Overview

WAVE Life Sciences's Return On Capital Employed Overview

WAVE Life Sciences (NASDAQ:WVE) brought in sales totaling $1.76 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 458.35%, resulting in a loss of $34.78 million.

Get all your
news in one place.

100’s of premium titles.
One news app.

Earnings Preview: WAVE Life Sciences

WAVE Life Sciences (NASDAQ:WVE) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts estimate that WAVE Life Sciences will report an earnings per share (EPS) of $-0.51.

Two Organizations To Support Wave Life Sciences' FTD, ALS Program

The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) will support Wave Life Sciences Ltd's (NASDAQ: WVE) amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) program.

People

Kritika SarmahHer

Steve Reitmeister

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Johnson & Johnson (

Medical Pharmaceuticals

BristolMyers Squibb Company

AstraZeneca Plc

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

254,160 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play